Cold Spring Harbor Scientists Devise Method of Sifting Genome’s High-Value Regions
News Nov 13, 2007
Scientists at Cold Spring Harbor Laboratory (CSHL) have developed a new means of extracting and interpreting data from the human genome that is more powerful and more economical than methods currently employed.
The new technology, called selective resequencing, promises to be a boon to many kinds of research, including efforts to comb vast stretches of the genome for mutant genes implicated in major diseases such as cancer and schizophrenia, according to scientists.
A team led by CSHL's Gregory Hannon, Ph.D. a molecular and cell biologist, and W. Richard McCombie, Ph.D., a molecular biologist who heads the Laboratory's gene sequencing center, sought an efficient way of separating what's most valuable in the genome from less important stretches of genomic "code." In all, there are over 3 billion "letters" of code in the human genome, only 2 percent of which actually instructs cells to produce proteins, the workhorses of all life processes.
CSHL's new method enables genome scientists to save time and labor by capturing and then sequencing, or "spelling out," genomic code culled from relatively small, focused areas - as opposed to sequencing the entire genome and only afterward honing in on areas of interest.
"In practical terms, this means that a new world of discovery is opening to scientists interested in studying the genomes of large groups of people on a comparative basis - which is a prime basis for our insights about gene mutations that cause disease," said Dr. Hannon.
Dr. McCombie added: "By enabling scientists to target a small fraction of the genome, our method makes it possible for people with interesting ideas, to do significant work, on a modest budget. This will afford researchers the opportunity to include enough samples to conduct truly meaningful genome-wide comparative studies."
The CSHL team's innovation is demonstrated in a paper appearing in the November 4, 2007 online edition of Nature Genetics.
A set of seven flexible, high-density microarrays, or gene-chips, were used to extract from a DNA sample only those stretches of genomic sequence that code for the manufacture of proteins. These segments, called exons, following their capture on the arrays were enriched and then sent to a sequencing machine.
The technique is called selective resequencing because it compares the newly obtained targeted sequences - in this case, of exons - with those of a "reference" version of the whole genome produced by the Human Genome Project.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.